Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the ...

Roger Li, MD, discusses the MoonRISe-1 study evaluating TAR-210 in FGFR-altered intermediate-risk non-muscle-invasive bladder cancer.

Dr. Daniel P. Petrylak discusses the different types of bladder cancer and how treatment options may vary based on disease ...

It is designed for intravesical dosing and intended to be an in-office ready-to-use therapy that is administered rapidly and requires no anesthesia or new or dedicated equipment to employ.

NDV-01 is a novel, investigational, sustained-release gemcitabine/docetaxel formulation, designed as a ready-for-use intravesical therapy for the treatment of NMIBC. The U.S. prevalence of NMIBC ...

CORAL GABLES, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology ...

Need for Targeted Therapy Current treatments for OAB include ... that applied to other studies reported at the same session. Intravesical instillation of a paclitaxel-containing solution led ...

Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical gemcitabine-releasing ... leaving patients with limited alternatives when initial ...

One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving ...

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application ...